First AD

Second AD

OncLive Peer Exchange® 

® Peer Exchange video program comprises lively expert panel discussions feature peer-to-peer exchanges providing authoritative insights, opinions, and perspectives on important issues facing today’s health care professionals. Episodes focus on updates and insights across solid and hematologic malignancies, including breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, gynecological cancers, and hematologic malignancies. 

Myeloproliferative Neoplasms

INC-22-OSD1258 - /clinical/myeloproliferative-neoplasms

The OncLive Myeloproliferative Neoplasms condition center is a comprehensive resource for clinical news and expert insights on myeloproliferative neoplasms, including myelofibrosis, polycythemia vera, and essential thrombocythemia. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in myeloproliferative neoplasms.

Hematologic Oncology

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Myelodysplastic Syndromes (MDS): Recent Updates and Evolving Treatment Paradigms

Peer Exchange

Yazan Madanat, MD, presents the patient profile of a transfusion-dependent 79-year-old man with lower-risk MDS and a KRAS mutation.

Patient Profile: A 79-Year-Old Man With Lower-Risk MDS and a KRAS Mutation

Diagnosing Myelodysplastic Syndromes (MDS)

Risk Stratification of MDS

First-Line Treatment Options for Lower-Risk MDS With Symptomatic Anemia

Initiating Treatment for Lower-Risk MDS With Symptomatic Anemia

Monitoring Treatment With ESAs for Lower-Risk MDS With Symptomatic Anemia

Second-Line Treatment Options for Lower-Risk MDS With Symptomatic Anemia

Patient Profile: A 75-Year-Old Man With Lower-Risk MDS and Symptomatic Anemia

Treatment Approaches for Lower-Risk MDS With Symptomatic Anemia

Treatment Approaches for Lower-Risk MDS With RAS Mutations

ESA Outcomes by SF3B1 Mutation Status in Lower-Risk MDS

Luspatercept for Lower-Risk MDS: Data From the COMMANDS Trial

Imetelstat for Lower-Risk MDS: Data From the IMerge Trial

Oral HMAs in Lower-Risk MDS Treatment

IRAK1 and IRAK4 Inhibitors for the Treatment of Lower-Risk MDS

Key Trials in the Treatment of Higher-Risk MDS

Final Thoughts on Recent Data Updates in MDS